Navigation Links
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
Date:3/24/2009

ABBOTT PARK, Ill., March 24 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced the initiation of the next phase of the ABSORB clinical trial to evaluate the safety and performance of the company's fully bioabsorbable drug eluting coronary stent. This second phase of the ABSORB clinical trial will enroll approximately 80 patients at 10 centers in Europe, Australia and New Zealand, and will incorporate device enhancements designed to improve deliverability and vessel support. The first patient was enrolled into the second stage of the ABSORB clinical trial at Onze Lieve Vrouw Ziekenhuis Hospital in Aalst, Belgium, by Bernard De Bruyne, M.D., Ph.D.

"Interventional cardiology has come a long way. It started with balloon angioplasty, which evolved into bare metal stents and then drug eluting metal stents were created," said Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, and principal investigator of the ABSORB trial. "Now we have the fourth revolution in interventional cardiology technology, and patient outcomes from the first stage of ABSORB clearly show that bioabsorbable devices are the future of coronary artery disease treatment."

Results from the first stage of the ABSORB trial with 30 patients demonstrated that Abbott's bioabsorbable everolimus eluting stent successfully treated coronary artery disease, and that at two years, the treated vessel was able to expand and contract, without being restricted by a permanent implant - indicating that the device was absorbed. In addition, there were no cases of thrombosis (blood clot formation) out to two years of follow-up, and no new major adverse cardiac events (MACE) between six months and two years, with the bioabsorbable device demonstrat
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
3. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
6. Abbotts Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
7. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
8. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... SAN DIEGO , Dec. 17, 2014 ... PHIA) and Volcano Corporation (NASDAQ: VOLC ), a ... applications, today announced that they have entered into a definitive ... tender offer to acquire all of the issued and outstanding ... total equity purchase price of USD 1 billion (approx. EUR ...
(Date:12/17/2014)... Germany , December 17, 2014 ... level of expenditure on research and development In ... increased its revenue by two percent to EUR 4.287 billion ... (EBIT) grew by 14 percent to EUR 360 million. "Overall, ... said Dr. Michael Kaschke , President and CEO of ...
(Date:12/17/2014)... 2014  Northstar Global Business Services, Inc. (OTCPink:MDIN) ... has made their final decision and has determined ... stock effective December 15, 2014, and has resumed ... and book entry transfer services. All deposit restrictions have ... again fully "DTC Eligible", and has resumed electronic ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8ZEISS Asserts its Position in Difficult Environment 2Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3
... 2010 General-use X-ray security systems are one ... to widespread use to check people entering secured ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... the low risk to health associated with these ...
... N.Y., Nov. 4, 2010 At a special meeting today, ... approve the merger of West Acquisition Corp., an indirect wholly ... ), with and into Penwest and voted to approve the ... Penwest, West and Endo.   The merger became ...
Cached Medicine Technology:
(Date:12/19/2014)... Novellus Healthcare Communications, LLC announces the ... an independent journal that provides practical information for ... patients inside the pharmacy and retail clinics. ... access to quality care, Inside Patient Care: Pharmacy ... treating and coordinating patient care in pharmacies and ...
(Date:12/19/2014)... Slone Partners , a national ... information technology, and laboratory testing industries, has promoted ... Officer. The announcement comes after a year of ... presence in Boston and several new additions to ... the client experience," said Adam Slone, Chief Executive ...
(Date:12/19/2014)... good shape seems to reduce your risk of high blood ... than 57,000 Americans, including more than 35,000 with high blood ... Those in the poorest shape had a more than 70 ... of the study, compared to a 50 percent chance for ... than 8,000 people diagnosed with high blood pressure during the ...
(Date:12/19/2014)... 18, 2014 (HealthDay News) -- Traveling through the same ... virus to three others within a four-hour time span, ... new report shows. "The exposures in this report ... than an international terminal, highlighting the fact that measles ... Vega, an infectious disease specialist at the U.S. Centers ...
(Date:12/17/2014)... 17, 2014 Unidesk Corporation today ... (ACOM), which welcomed its inaugural class in August ... to seamlessly support bring your own device (BYOD) ... – experience. The solution, comprised of Citrix ... Dell server and storage infrastructure and ...
Breaking Medicine News(10 mins):Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3
... April 15 SpectraScience, Inc. (OTC,Bulletin Board: SCIE), a San ... its annual shareholders meeting at 9:00 AM on,May 5, 2008 ... who held SpectraScience stock as of the close of business,on ... for the meeting are,entitled to attend in person., Jim ...
... waists. Healthier blood,pressure. Less risk for diabetes and ... for most adults. Here,s more on one popular ... Listen to this report from Apple Products Research ... journalists can access video, audio, text, graphics and,photos ...
... HealthSouth,Corporation (NYSE: HLS ) today announced it will ... on Wednesday, May 7, 2008, to discuss its,results for ... may be accessed by dialing 866-406-5369 and giving,the pass ... same pass code. Please call approximately 10 minutes before ...
... genetic determinants of resistance to the anti-cancer drug methotrexate ... pathway to predicting such resistance and treatments to overcome ... study. , Besides its use in ALL, methotrexate is ... diseases. However, until the new study there was no ...
... MODESTO, Calif., April 15 emebaVet, LLC, ... signage solutions and systems,integration, is teaming with ... pet forecasts from weather.com for their emebaVet,Client ... Interactive definitely enhances our emebaVet,Client Education System," ...
... Clothes Off Our Back(R) with Online ... Celebrity Shoe Auction, KENILWORTH, N.J., ... like one on the dance floor? DR. SCHOLL,S(R) FOR,HER and Julianne Hough, ... have partnered to raise money for,the charity foundation, Clothes Off Our Back(R). ...
Cached Medicine News:Health News:Annual Shareholders Meeting to Be Held May 5, 2008 at the University Club in St. Paul, MN 2Health News:HealthSouth Announces Date of 2008 First Quarter Earnings Conference Call 2Health News:St. Jude gene study reveals basis of anticancer drug resistance in childhood leukemia 2Health News:St. Jude gene study reveals basis of anticancer drug resistance in childhood leukemia 3Health News:emebaVet Adds 'Pet Friendly' Forecast From the Weather Channel 2Health News:Video: Julianne Hough From Dancing With the Stars(TM) Has a New Partner: DR. SCHOLL'S(R) FOR HER 2Health News:Video: Julianne Hough From Dancing With the Stars(TM) Has a New Partner: DR. SCHOLL'S(R) FOR HER 3
0.25 mm diameter textured tip with protective guard....
... design has been carefully considered with both the ... ensures the optimum viewing angle and the largest ... aligned for perfect focus where it is needed ... This along with Keeler's wide angle light ...
A full function instrument at an economical price....
... The ophthalmoscope with superior aspherical optics. ... by means of the aspherical optical system ... Beta 200 allows you to view the ... retina even with a small pupil. Conventional ...
Medicine Products: